Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

• Status: Recruiting
• Trial end date: 2026-04-01
• Target enrollment: 0
• Participant gender: Female

Summary

stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Netherlands Cancer Institute
• Treatments: Cisplatin

Criteria

Inclusion Criteria:

• candidate for primary CRS

• histological or cytological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer

Exclusion Criteria:

• history of previous malignancies within 5 years prior to inclusion

• FIGO stage IV disease

• complete primary cytoreduction is impossible

• prior treatment for the current malignancy